The present study aimed to determine the expression of microRNA (miRNA or miR)-145 in hypertrophic scars at the tissue and cellular levels, and to investigate its biological functions and mechanism of action. A total of 36 patients who were diagnosed with hypertrophic scar were included in the present study. Reverse transcription-quantitative polymerase chain reaction was used to determine the expression of miR-145 in tissues and fibroblasts. Primary fibroblasts were transfected with negative control miRNA, miR-145 mimics or inhibitor. A Cell Counting Kit-8 assay was performed to determine the level of proliferation of fibroblasts. Flow cytometry was employed for cell cycles determination and apoptosis in fibroblasts. A Matrigel assay was used to evaluate the invasion ability of fibroblasts. Western blotting was used to determine the expression of the transcription factor SOX-9 (SOX-9) protein in fibroblasts. Rescue experiments were performed to examine the effect of SOX-9 on the regulation of fibroblasts by miR-145. The dual luciferase reporter assay was performed to identify the direct interaction between SOX-9 and miR-145. The expression of miR-145 was reduced in hypertrophic tissues and fibroblasts. Overexpression of miR-145 inhibited the proliferation, G1/S phase transition and invasion of fibroblasts, and promoted the apoptosis of fibroblasts. In addition, overexpression of miR-145 inhibited SOX-9 protein expression. By contrast, the expression of SOX-9 reversed the effects of miR-145 on the proliferation, cell cycle, apoptosis and invasion of fibroblasts. The miR-145 seed region was able to bind with the 3'-untranslated region of the SOX-9 mRNA to regulate its expression. The present study demonstrated that miR-145 expression is reduced in hypertrophic scar tissues and negatively associated with SOX-9 expression. In addition, miR-145 inhibits the proliferation, cell cycle and invasion, and promotes the apoptosis of fibroblasts by down-regulating the expression of SOX-9. The current study provides a potential target for the clinical diagnosis and treatment of hypertrophic scars.
Introduction
A hypertrophic scar is a clinically common skin fibroplasia disease that is caused by an excessive healing response of the human body to trauma (1) . It is characterized by the abnormal proliferation of fibroblasts, abundant collagen synthesis and excessive collagen deposition (2) . It was recently reported that the incidence of hypertrophic scars in burn patients in China reached 90% (3) . Scar formation affects a patient's appearance, and results in contracture that may lead to different degrees of dysfunctions including tendon contracture, joint dislocation and dyskinesia (4, 5) . At present, the pathogenesis of hypertrophic scar has not been fully elucidated. It is widely accepted that fibroblasts are the major effector cells in hypertrophic scars, and abnormal cell proliferation and extracellular matrix deposition are the main characteristics of hypertrophic scars (6) . The transforming growth factor (TGF)-GFmothers against decapentaplegic homolog (SMAD) signaling pathway is closely associated with a variety of physiological and pathological processes including collagen metabolism and the proliferation, differentiation, migration and apoptosis of fibroblasts (7, 8) . Therefore, studies on the TGF-β/SMAD signaling pathway in fibroblasts are important to elucidating the mechanisms of formation and development in hypertrophic scars. microRNAs (miRNAs or miRs) form a class of non-encoding small RNA molecules with 18-24 nucleotides. miRNA molecules bind with the 3'-untranslated region (UTR) of mRNA to inhibit its translation into proteins, and are associated with the regulation of pathophysiological processes including cell proliferation, migration, apoptosis, autophagy, differentiation and tumor formation (9, 10) . It has been reported that miRNAs regulate the formation and repair of skin and its accessory organs, suggesting that miRNAs serve important roles in hypertrophic scar (11) . In addition, the abnormal expression of miRNA molecules was identified in hypertrophic scar tissues, suggesting that miRNA molecules are associated with the formation of scar tissues (12) . Notably, miR-145 was revealed to be closely associated with tumorigenesis, myocardial injury and angiogenesis (13) . For example, Yuan et al (14) demonstrated that miR-145 regulates myocardial ischemic injury by inhibiting the expression of cluster of differentiation (CD)40. Additionally, reduced miR-145 expression in peripheral blood has clinical diagnostic value in patients with coronary heart disease (15) . miR-145 inhibits the proliferation and migration of lung cancer cells by regulating the expression of cadherin-2 (16) . The aforementioned study also demonstrated that miR-145 is associated with the occurrence and development of hypertrophic scars (16) . Zhu et al (17) reported that a peroxisome proliferator-activated receptor-agonist upregulates the expression of miR-145, and inhibits the TGF-β/SMAD3 signaling pathway and hypertrophic scar formation. However, the target genes of miR-145 associated with the regulation of hypertrophic scars and the expression of miR-145 in hypertrophic scar tissues remain unclear. In the present study, the expression of miR-145 in hypertrophic scar tissues was measured and its mechanism of action was investigated.
Materials and methods
Patients. A total of 36 patients (21 males and 15 females) who were diagnosed with hypertrophic scars and received dermoplasty between May 2013 and June 2016 at The First Affiliated Hospital (Hangzhou, China) were included in the present study. The age range of the patients was 23-43 years and hyperplasia duration was between 3 months and 2 years. Skin damage sites exhibited hyperemia redness and lesions that did not exceed wound surface. The inclusion criteria were: i) Patients with hypertrophic scar tissues identified by clinicians; ii) patients without pituitary or adrenal diseases, infectious diseases, skin diseases, immune diseases, local infection or ulcer; and iii) patients not currently taking prescribed treatments. Patients with other tumors, chronic basic disease or a long history of drug intake were excluded. Hypertrophic scar tissues collected from all patients were used as the experimental group. For the control group, normal skin tissues from the hypogastrium of respective patients were used. The tissues were frozen and stored in liquid nitrogen. All procedures were approved by the Ethics Committee of Zhejiang University (Hangzhou, China). Written informed consent was obtained from all patients or their families.
Cells.
Collected hypertrophic scar and control tissue samples were washed with PBS containing 100 µ/ml penicillin and streptomycin 3 times prior to removing epidermal and adipose tissues. The samples were cut into 1 mm 3 sections, and washed with PBS containing 100 µ/ml penicillin and streptomycin 2 times. Subsequently, the samples were placed into culture flasks, and Dulbecco's modified Eagle medium (DMEM; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was added prior to incubation at 37˚C and 5% CO 2 . After 2 h, 2 ml DMEM containing 10% fetal bovine serum (Thermo Fisher Scientific, Inc.) was added into the flasks. One week later, spindle shape fibroblasts were observed around the tissue samples in the flasks under a light microscope (magnification, x200). Next, the tissues and culture medium were discarded, and fresh DMEM with 10% fetal bovine serum was added to the remaining fibroblasts in the culture flask. Once the cells reached 80% confluence, they were passaged and cells in 3-5 passages were used for subsequent experiments. A strain of hypertrophic scar fibroblasts (HSFB) and a strain of normal colonic fibroblasts (NCFB) were obtained.
Prior to transfection, fibroblasts in log-phase growth (2x10 5 ) were seeded onto 24-well plates containing antibiotic-free DMEM supplemented with 10% fetal bovine serum and cultured at 37˚C. Once the cells reached 70% confluence, the cells were collected for transfection.
Transfection. In the first vial, 1.5 µl miR-negative control (NC group; 20 pmol/µl; Hanbio Biotechnology Co., Ltd., Shanghai, China), miR-145 inhibitors (20 pmol/µl; the inhibitor group; 5'-GGA UUC CTG GAA ATA CTG TTCT-3'; Hanbio Biotechnology Co., Ltd.) or mimics (20 pmol/µl; the mimics group; 5'-GTC CAG TTT TCC CAG GAA TCC CT-3'; Hanbio Biotechnology Co., Ltd.) was mixed with 50 µl Opti-MEM medium (Thermo Fisher Scientific, Inc.). In another vial, 1 µl Lipofectamine ® 3000 Transfection Reagent (Thermo Fisher Scientific, Inc.) was mixed with 50 µl Opti-MEM medium. The aforementioned two vials were incubated at room temperature for 5 min, and then combined prior to incubation for 20 min at room temperature. The mixtures were subsequently added to the cells in respective groups at room temperature. A total of 6 h later, the medium was replaced with DMEM containing 10% fetal bovine serum. After culturing at 37˚C for 48 h, the cells were collected for further assays.
For rescue experiments, fibroblasts (1x10 5 cells) in the miR-145 mimics and inhibitors groups were seeded onto 24-well plates containing antibiotic-free DMEM supplemented with 10% fetal bovine serum at 37˚C. Once the cells reached 60% confluence, fibroblasts in the miR-145 mimics and inhibitors groups were transfected with 0.5 µl pLKO.1-sh-sox9 and pcDNA3.1-SOX-9 plasmids (Hanbio Biotechnology Co., Ltd.), respectively, using Lipofectamine ® 3000, and named the miR-145 mimics + pLKO.1-sh-sox9 group and the miR-145 inhibitor + pcDNA3.1-SOX-9 group. After incubation at 37˚C and under 5% CO 2 for 6 h, the medium was changed to fresh DMEM containing 10% fetal bovine serum prior to continued cultivation for 72 h.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Hypertrophic scar and control tissues (100 mg) were ground into powder using liquid nitrogen and lysed with 1 ml TRIzol™ Reagent (Thermo Fisher Scientific, Inc.). Then, total RNA was extracted using the phenol chloroform method (18) . The purity of RNA was determined by the A260/A280 ratio using ultraviolet spectrophotometry (NanoDrop™ 2000; Thermo Fisher Scientific, Inc.). cDNA was obtained by reverse transcription from 1 µD RNA and stored at -20˚C. Reverse transcription was performed using miScript II RT kit (Qiagen GmbH, Hilden, Germany) following the manufacturer's protocol.
The expression of miRNA was determined by miScript SYBR ® Green PCR kit (Qiagen GmbH) using U6 (forward, 5'-CTC GCT TCG GCA GCA CA-3'; reverse, 5'-AAC GCT TCA CGA ATT TGC GT-3') as an internal reference. The reaction mixture (20 µ 20 contained 10 µl RT-qPCR-Mix, 0.5 µM upstream primer (miR-145, 5'-GTC CAG TTC CCA GGA ATC CCT-3'), 0.5 µ, downstream universal primer (provided in PCR kit), 2 µk cDNA and 7 µc double-distilled H 2 O, and was performed using an iQ5 thermocycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The reaction protocol was as follows: Initial denaturation at 95˚C for 10 min, and 40 cycles of 95˚C for 1 min and 60˚C for 30 sec. The 2 -ΔΔCq method (19) was used to calculate the relative expression of miR-145 by comparing it against the expression of the internal reference. Each sample was tested in triplicate.
Cell counting Kit (CCK)-8 assay. Cells in each group were seeded at a density of 2,000 cells/well in 96-well plates at 37˚C. At 0, 24, 48 and 72 h, 20 µl CCK-8 (5 g/l; Beyotime Institute of Biotechnology, Shanghai, China) was added to the cells and incubated at 37˚C for 2 h. The absorbance of each well was measured at 490 nm and cell proliferation curves were plotted. Each group was tested in 3 replicate wells and the mean value was calculated.
Flow cytometry. Cells in each group were seeded onto 12-well plates in triplicate at a density of 2x10 5 cells/well at 37˚C. A total of 24 h later, the cells were harvested and the cell cycle was determined using Cycletest™ Plus DNA Reagent kit (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's protocol. Briefly, the cells were incubated with 150 µi liquid A at room temperature for 10 min, and 150 µl liquid B for a further 10 min. Cells were subsequently incubated with 120 µl liquid C in the dark for 10 min before analysis with a FACSCanto II Flow Cytometer (BD Biosciences). The result was analyzed using ModFit software (version 3.2; Verity Software House, Inc., Topsham, ME, USA).
To detect cell apoptosis, FITC Annexin V Apoptosis Detection Kit I (BD Biosciences) was used. Briefly, the cells were trypsinized and centrifuged at 500 x g at room temperature for 3 min. Then, the cells were washed with precooled PBS twice and centrifuged at 500 x g at room temperature for 3 min. Following the removal of the supernatant, 5 µl Annexin V-fluorescein isothiocyanate and 5 µn propidine iodide staining solutions were added to the cells, and the samples were incubated in dark at room temperature for 15 min prior to flow cytometry. The result was analyzed using ModFit software.
Matrigel assay. Matrigel was thawed at 4˚C overnight and diluted with serum-free DMEM medium (dilution 1:2). The mixture (50 µ o was evenly smeared into the upper chamber of Transwell plates (Merck KGaA, Darmstadt, Germany) and incubated at 37˚C for 1 h. Following the solidification of the gel, 1x10 5 cells from each group were seeded into the upper chamber containing 200 µl serum-free DMEM medium. In addition, 500 µl DMEM medium supplemented with 10 % fetal bovine serum was added into the lower chamber. After 24 h, the chamber was removed and the cells in the upper chamber were discarded. Following fixation at room temperature with 4% formaldehyde for 10 min, the membrane was stained using the Giemsa method (20) for light microscopic observation of 5 random fields (magnification, 200x). The number of Transwell cells was calculated for the evaluation of cell invasion ability. All procedures were carried out on ice with pipetting tips being precooled at 4˚C.
Western blotting. Cells in each group were trypsinized and collected. Then, precooled Radio-Immunoprecipitation Assay (RIPA) lysis buffer (600 µl; 50 mM Tris-base, 1 mM EDTA, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 1% TritonX-100, 1% sodium deoxycholate; Beyotime Institute of Biotechnology) was added to the samples. Following lysis for 30 min on ice, the mixture was centrifuged at 12,000 x g and 4˚C for 10 min. The supernatant was used to determine protein concentration by bicinchoninic acid protein concentration determination kit (cat. no. RTP7102; Real-Times Biotechnology Co., Ltd., Beijing, China). Protein samples (6 µl/lane) were then mixed with 5X SDS loading buffer prior to denaturation in a boiling water bath for 10 min. The samples were then separated by 10% SDS-PAGE (100V). The resolved proteins were transferred to polyvinylidene difluoride membranes on ice (250 mA, 1 h) and blocked with 5% skimmed milk at room temperature for 1 h. Then, the membranes were incubated with rabbit anti-human SOX-9 polyclonal (1:1,000; cat. no. sc-20095) and GAPDH (1:4,000; cat. no. sc-293335; both Santa Cruz Biotechnology, Inc., Dallas, TX, USA) primary antibodies at 4˚C overnight. Following extensive washing with Tween 20 in PBS 5 times (5 min each), the membranes were incubated with goat anti-rabbit (cat. no. sc-2007) and goat anti-mouse (cat. no. sc-2039) horseradish peroxidase-conjugated secondary antibodies (1:4,000; Santa Cruz Biotechnology, Inc.) for 1 h at room temperature prior to washing with Tween 20 in PBS 5 times (5 min each). Subsequently, the membrane was developed with the enhanced chemiluminescence detection kit (Sigma-Aldrich; Merck KGaA) for imaging. Image lab software (version 3.0; Bio-Rad Laboratories, Inc.) was used to analyze imaging signals. The relative content of SOX-9 protein was expressed as a SOX-9/GAPDH ratio.
Dual luciferase reporter assay. According to bioinformatics results (www.targetscan.com), wild-type (WT) and mutant seed regions of miR-145 in the 3'-UTR of SOX-9 gene were chemically synthesized in vitro. The seed regions were cut with Spe-1 and HindIII restriction sites, and then cloned into pMIR-REPORT luciferase reporter plasmids (Thermo Fisher Scientific, Inc.). Plasmids (0.5 µg) with WT or mutant 3'-UTR DNA sequences were co-transfected with miR-145 mimics into 293T cells (Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China) using Lipofectamine 3000 (Thermo Fisher Scientific, Inc.). After cultivating at 37˚C for 24 h, the cells were lysed using dual luciferase reporter assay kit (Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol, and fluorescence intensity was measured using a GloMax 20/20 luminometer (Promega Corporation). Using Renilla luciferase activity as an internal reference, the luciferase activity of each group of cells was measured.
Statistical analysis.
Results were analyzed using SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, USA). Data are presented as mean ± standard deviation. The differences between datasets containing multiple groups were analyzed using one-way analysis of variance followed by Tukey's test. Differences between datasets containing two groups were analyzed using a Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results
Expression of miR-145 is reduced in hypertrophic tissues and fibroblasts. To measure the expression of miR-145 in hypertrophic scar tissues and fibroblasts, RT-qPCR analyses were performed. The data demonstrated that the expression of miR-145 in hypertrophic scar tissues was significantly reduced compared with that of the control tissues (P<0.05; Fig. 1A) . Similarly, the expression of miR-145 in HSFB was significantly lower than that in NCFB (P<0.05; Fig. 1B ). These results demonstrate that expression of miR-145 is reduced in hypertrophic tissues and fibroblasts.
Overexpression of miR-145 inhibits the proliferation of fibroblasts in vitro.
To determine fibroblast proliferation, a CCK-8 assay was performed. The data revealed that the absorbance of HSFB transfected with miR-145 mimics was significantly lower than that of HSFB transfected with miR-NC at 24, 48 and 72 h (all P<0.05; Fig. 2A ). In addition, the absorbance of NCFB transfected with miR-145 inhibitor was significantly higher than that of NCFB transfected with miR-NC at 24, 48 and 72 h (all P<0.05; Fig. 2B ). These results indicate that miR-145 overexpression inhibits the proliferation of fibroblasts in vitro.
Overexpression of miR-145 delays G1/S phase transition of fibroblasts. For cell cycle determination, flow cytometry was performed. The data revealed that G1/S phase transition of HSFB transfected with miR-145 mimics was reduced (P<0.05; Fig. 3A ), whereas G1/S phase transition of NCFB transfected with miR-145 inhibitors was promoted (P<0.05; Fig. 3B ). These result suggest that overexpression of miR-145 delays G1/S phase transition of fibroblasts.
Overexpression of miR-145 promotes apoptosis of fibroblasts.
To examine cell apoptosis, flow cytometry was performed. The data demonstrated that the apoptotic rate of HSFB transfected with miR-145 mimics was significantly higher than that in the miR-NC group (P<0.05; Fig. 4A ), whereas the apoptotic rate of NCFB transfected with miR-145 inhibitors was significantly lower than that in the miR-NC group (P<0.05; Fig. 4B ). These results indicate that overexpression of miR-145 promotes the apoptosis of fibroblasts.
Overexpression of miR-145 suppresses invasion of fibroblasts.
To determine the invasion ability of fibroblasts, a Matrigel assay was employed. The data revealed that the number of HSFB that crossed the membrane in the miR-145 mimics group was significantly lower than that in the miR-NC group (P<0.05; Fig. 5A ). In addition, the number of NCFB that crossed the membrane in the miR-145 inhibitor group was significantly higher than that in the miR-NC group (P<0.05; Fig. 5B ). These results suggest that overexpression of miR-145 suppresses invasion of fibroblasts.
Overexpression of miR-145 may inhibit SOX-9 protein expression. To measure the expression of SOX-9 protein, western blotting was performed. The data demonstrated that the expression of SOX-9 in hypertrophic fibroblasts transfected with miR-145 mimics was significantly reduced compared with that in hypertrophic fibroblasts transfected with miR-NC (P<0.05; Fig. 6A ). By contrast, the expression of SOX-9 in normal fibroblasts transfected with miR-145 inhibitors was significantly enhanced compared with that in normal fibroblasts transfected with miR-NC (P<0.05; Fig. 6B ). The results indicate that overexpression of miR-145 inhibits SOX-9 protein expression.
Expression of SOX-9 can reverse the effects of miR-145 on the proliferation, cell cycle, apoptosis and invasion of fibroblasts.
To test whether miR-145 affects the biological functions of fibroblasts by regulating the expression of SOX-9 protein, CCK-8, flow cytometry and Matrigel assay were performed. These assays analyzed the proliferation, cell cycle determination, apoptosis rate and invasion of fibroblasts transfected with miR-145 mimics or inhibitors following the overexpression of the SOX-9 protein by a plasmid containing the SOX-9 gene or the silencing of the SOX-9 protein by a plasmid containing a SOX-9 shRNA, respectively. The CCK-8 assay revealed that the downregulation of SOX-9 expression by the SOX-9 shRNA in miR-145 inhibitor-transfected NCFB significantly decreased cell proliferation compared with NCFB transfected with miR-145 inhibitors alone and miR-NC (P<0.05; Fig. 7A ), whereas the overexpression of SOX-9 by the plasmid containing the SOX-9 gene in miR-145 mimic-transfected HSFB significantly decreased cell proliferation compared with HSFB transfected with miR-145 mimics alone and miR-NC (P<0.05; Fig. 7B ). Flow cytometry demonstrated that the overexpression of SOX-9 significantly enhanced the G1/S phase transition of HSFB transfected with miR-145 mimics compared with HSFB transfected with miR-145 mimics alone and miR-NC (P<0.05; Fig. 7C ), whereas downregulation of SOX-9 expression significantly decreased the G1/S phase transition of NCFB transfected with miR-145 inhibitors compared with NCFB transfected with miR-145 inhibitors alone and miR-NC (P<0.05; Fig. 7D ). Overexpression of SOX-9 significantly decreased the apoptotic rate of HSFB transfected with miR-145 mimics compared with HSFB transfected with miR-145 mimics alone and miR-NC (P<0.05; Fig. 7E ) and the downregulation of SOX-9 expression significantly decreased the apoptotic rate of NCFB transfected with miR-145 inhibitors compared with NCFB transfected with miR-145 inhibitors alone and miR-NC (P<0.05; Fig. 7F ). The Matrigel assay demonstrated that the overexpression of SOX-9 significantly increased the number of transmembrane HSFB transfected with miR-145 mimics compared with HSFB transfected with miR-145 mimics alone and miR-NC (P<0.05; Fig. 7G ) and the down-regulation of SOX-9 expression significantly decreased the number of transmembrane NCFB transfected with miR-145 inhibitors compared with NCFB transfected with miR-145 inhibitors alone and miR-NC (P<0.05; Fig. 7H ). These results demonstrate that the expression of SOX-9 reverses the effects of miR-145 on the proliferation, cell cycle determination, apoptosis and invasion of fibroblasts.
miR-145 binds with the 3'-UTR of the SOX-9 mRNA to regulate SOX-9 protein expression. To identify the interaction between the seed region of miR-145 and the 3'-UTR of SOX-9 mRNA, a dual luciferase reporter assay was performed. The fluorescence value of cells co-transfected with miR-145 mimics and pMIR-REPORT-WT luciferase reporter plasmids was significantly lower than that in the negative control group (P<0.05; Fig. 8 ). By contrast, no significant differences were identified between the fluorescence value of cells co-transfected with miR-145 mimics and pMIR-REPORT-mutant luciferase reporter plasmids, and that of the NC group. The result indicates that the miR-145 seed region can bind with the 3'-UTR of the SOX-9 mRNA to regulate SOX-9 protein expression.
Discussion
Fibroblasts are the major effector cells in wound healing (21) . In the process of hypertrophic scar formation, fibroblasts typically exhibit excessive proliferation, enhanced migration and inhibited apoptosis, and secrete abundant extracellular matrix (22, 23) . It was previously identified that miRNA molecules serve important roles in the biological functions of hypertrophic scar fibroblasts, but their mechanisms of action requires further elucidation (24) . In the present study, it was identified that miR-145 expression is significantly downregulated in hypertrophic scar tissues, suggesting that miR-145 may be associated with the occurrence and development of hypertrophic scar. In vitro experiments revealed that miR-145 inhibits the proliferation, invasion and G1/S phase transition of fibroblasts, and promotes the apoptosis of fibroblasts. Bioinformatics and molecular biology experiments demonstrated that miR-145 exerts these effects by regulating SOX-9 gene expression. Therefore, miR-145 may be a potential therapeutic target in the treatment of hypertrophic scar. As an important class of post-transcriptional regulators, miRNA molecules are widely associated with the proliferation, aging, apoptosis and migration of skin fibroblasts (25). For example, Xie et al (26) revealed that miR-377 facilitates the aging of skin fibroblasts by targeting the DNA (cytosine-5)-methyltransferase 1 mRNA. Zeng et al (27) demonstrated that miR-27b inhibits the activation of fibroblasts by regulating the TGF-β signaling pathway. Li et al (28) reported that miR-19 inhibits the release of cytokines from fibroblasts by targeting Toll-like receptor 2 mRNA. In vitro experiments demonstrated that miR-145 expression in HSFB is significantly lower than that in NCFB, suggesting that miR-145 has regulatory roles in biological functions of fibroblasts. It was reported that miR-145 regulates the TGF-βGF-rted that miR-145 regulates is significantly lower than that in NCFB, subcomponents by fibroblasts and the formation of hypertrophic scar (17) . The aforementioned study is consistent with the results of the current study.
An miRNA may regulate multiple target genes (29) . A recent study revealed that miR-145 targets SMAD3 expression and exerts its biological functions in fibroblasts (14) . However, it remains unclear whether miR-145 regulates hypertrophic scar formation via other target mRNA. SOX-9 is a member of the SOX gene family, which is closely associated with the proliferation, apoptosis and differentiation of cells (30) . For example, SOX-9 gene transcription regulates the activity of the wnt signaling pathway in intestinal epithelial stem cells (31) . In addition, SOX-9 promotes the proliferation, migration and differentiation of multiple tumor cells, including lung cancer, thyroid carcinoma and gastric cancer (32) . Furthermore, SOX-9 mRNA is regulated by several miRNA molecules. It was recently demonstrated that miR-105 inhibits the occurrence and development of glioma by targeting SOX-9 (33) . miR-592 also suppresses the proliferation and metastasis of non-small cell lung cancer by downregulating the expression of SOX-9 (34) . It was also reported that miR-124, miR-30a and miR-494 directly regulate the expression of the SOX-9 gene (35) (36) (37) . In the present study, bioinformatics revealed that SOX-9 is a potential target gene of miR-145, and that miR-145 expression is negatively associated with SOX-9 expression. Notably, rescue experiments demonstrate that miR-145 exerts its biological functions in fibroblasts by regulating SOX-9. Importantly, dual luciferase reporter assay identified that SOX-9 is a direct target gene of miR-145.
In conclusion, the present study demonstrated that miR-145 expression is downregulated in hypertrophic scar tissues. In addition, miR-145 inhibited fibroblast proliferation and invasion, and promoted the apoptosis of fibroblasts by targeting SOX-9 expression. Therefore, it is suggested that miR-145 regulates the occurrence and development of hypertrophic scars. The results of the current study may provide a potential target for the clinical diagnosis and treatment of hypertrophic scars.
